NCT06742281已完成2 期
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- CyanVac LLC
- 入组人数
- 432
- 试验地点
- 101
- 主要终点
- Percentage of participants with symptomatic COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula) to compare differences in relative vaccine efficacy.
研究概览
简要总结
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants.
详细描述
This is a double-blind, active comparator-controlled Phase 2b study to evaluate the efficacy, immunogenicity, and safety study in which eligible adult participants will be randomized 1:1 to receive CVXGA (CVXGA50) or COMIRNATY.
Number of Participants:
The proposed enrollment for this study is approximately 434 participants, that includes 16 participants enrolled in Sentinel Cohort 1 and Sentinel Cohort 2 (8 participants in each cohort).
Treatment Assignment:
Participants in Sentinel Cohort 1 and Sentinel Cohort 2 will be assigned to receive a single dose of CVXGA (CVXGA50) intranasally and will not receive an IM placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is an adult ≥18 years of age at time of screening.
- •Has completed any WHO/FDA-authorized or approved primary COVID-19 vaccination series.
- •Has received last COVID-19 vaccine no less than 6 months prior to study enrollment (study vaccination).
- •If a female of childbearing potential who is sexually active, agrees to use an adequate method of birth control from Screening through 90 days after last study vaccination, and has used an adequate birth control method for at least 30 days prior to Screening.
- •A. Female of childbearing potential is defined as post onset menarche and pre-menopausal person capable of becoming pregnant. This does not include females who meet any of the following conditions: a) menopausal >2 years; b) tubal ligation >1 year; c) bilateral salpingo-oophorectomy; or d) hysterectomy.
- •B. Adequate contraception is defined as a contraceptive method with a failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label. Examples include: oral contraceptives, either combined or progestogen alone; injectable progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device or intrauterine system; the female participant has exclusively female sexual partners; partner is sterile or otherwise unable to produce sperm (information on the person's sterility can come from the site personnel's review of the participant's medical records or interview with the participant regarding her medical history); male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); or male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
- •Is medically stable, as determined by the site investigator (based on review of health status, vital signs, medical history, and physical examination).
- •Agrees to not participate in any other SARS-CoV-2 infection prevention trial (vaccine, drug, biologic, or pre-exposure prophylaxis [PrEP]) during participation in the study.
- •Willing and able to provide informed consent prior to initiation of study procedures.
- •Is available for all study visits, willing to participate in all study procedures, and not planning to relocate from the area for the duration of the study.
排除标准
- •Has an acute illness, as determined by the site investigator, within 72 hours prior to Screening or study vaccination.
- •(a. An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol.)
- •Has had a positive COVID-19 test within the 90 days prior to Screening or study vaccination.
- •Current or planned participation in any other interventional clinical trial.
- •Prior receipt of a PIV5-based vaccine (e.g., CVXGA1, CVXGA35, or BLB201 [an RSV vaccine being developed by CyanVac/Blue Lake Biotechnology]).
- •Participation in research involving any investigational product within 45 days prior to Screening or study vaccination.
- •Receipt of any approved or authorized products intended to prevent SARS-CoV-2 infection within 6 months prior to Screening (complete list provided in the pharmacy manual).
- •Receipt or anticipated receipt of, within 7 days prior through 31 days after study vaccination, any intranasal medication including FDA approved prescription or over-the-counter products or non-FDA approved alternative medicine products (e.g., intranasal Fluticasone {commonly used intranasal products that would be used, which is not herbal/naturopathic}, Ayurvedic oil or other naturopathic substances).
- •Anticipated use of nasal irrigation (e.g., Neti PotTM) from Screening through 31 days after study vaccination.
- •Receipt of blood products or immunoglobulins within 60 days prior to Screening or study vaccination.
- •Received influenza vaccination within 14 days prior to Screening or study vaccination, or any other vaccine within 30 days prior to Screening or study vaccination.
- •Any significant or uncontrolled autoimmune, immunodeficiency disease/condition, or autoinflammatory disorder (e.g. untreated or advanced human immunodeficiency virus [HIV] infection with CD4 counts <200 cells/mm3, history of acquired immunodeficiency syndrome [AIDS] defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV).
- •Unstable illness (acute or chronic illness) requiring significant medical monitoring and intervention during the 90 days prior to Screening or study vaccination.
- •History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or presence of any medical condition that, in the opinion of the investigator, increases risk of myocarditis or pericarditis.
- •Administration of immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs within the following timeframes:
- •B-cell therapies within the 6 months prior to Screening or study vaccination.
- •Prednisone, ≥20 mg for more than 2 weeks, within the 30 days prior to Screening or study vaccination.
- •Monoclonal antibodies that may suppress aspects of immune response (e.g., Dupixent) within the 6 months prior to Screening or study vaccination.
- •Other medications in this category, including but not limited to high-dose inhaled corticosteroids (>800 mcg/day of beclomethasone dipropionate or equivalent); antimetabolites; transplant immunosuppressive agents; alkylating agents; cell-depleting agents; or cancer chemotherapeutics, within the 90 days prior to Screening or study vaccination.
- •Any medication for any period of time that, in the opinion of the site investigator, could impede immune response to vaccination.
- •Individuals who have close contact or high-risk contact with persons who may be severely immunocompromised, within 14 days following the study vaccination. High-risk contacts include but are not limited to:
- •Residents of nursing homes or rehabilitation facilities
- •Persons of any age with any significant immunodeficiency disease (e.g., untreated or advanced HIV, history of AIDS, or clinical manifestations of HIV)
- •Persons of any age being administered immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs
- •Persons of any age with a known history of significant airway reactivity to viruses (e.g., severe asthma, advanced chronic obstructive disease, or cystic fibrosis)
- •Persons of any age immunosuppressed due to cancer or undergoing active treatment for cancer
- •Women who are pregnant, breastfeeding, or who plan to become pregnant during the study; and
- •Infants age ≤6 months.
- •Known contraindication to IM injection (e.g., bleeding diathesis, acquired coagulopathy) or to intranasal administration (e.g., severe nasal obstruction, significant chronic rhinitis, nasal septal defect causing significant breathing problems, unrepaired cleft palate, nasal polyps, or other nasal abnormality that, in the opinion of the investigator, may affect vaccine administration).
- •History of significant/severe wheezing or respiratory symptoms resulting in hospitalization or known bronchial hyperreactivity to viruses.
- •History of severe adverse reaction to vaccination in the past, including to COVID-19 vaccination.
- •Any known allergies to components contained in CVXGA or COMIRNATY (including polyethylene glycol [PEG] allergies), or latex.
- •Women who are pregnant, breastfeeding, or who plan to become pregnant during the study.
- •Any other condition that, in the opinion of the site investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the investigational product or interpretation of study results.
- •Study team member or first-degree relative of any study team member (inclusive of CyanVac and site personnel involved in the study).
研究组 & 干预措施
CVXGA (CVXGA50)
Experimental
CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
干预措施: CVXGA (CVXGA50) (Biological)
COMIRNATY®
Active Comparator
COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH [Mainz, Germany] and Pfizer Inc. [New York, NY]) will be used as the comparator vaccine for this study.
干预措施: COMIRNATY® (Biological)
结局指标
主要结局
Percentage of participants with symptomatic COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula) to compare differences in relative vaccine efficacy.
时间窗: Day 14 to Day 366 post-vaccination.
First occurrence of molecularly confirmed (RT-PCR-positive) symptomatic COVID-19 according to the case definition with onset at least 14 days post-vaccination through 12 months post-vaccination. Case definition: Virologically confirmed SARS-CoV-2 infection (by RT-PCR) with 1 or more of the following symptoms within ±7 days: * Fever or chills * Cough * Shortness of breath or difficulty breathing * Fatigue * Muscle or body aches * Headache * New loss of taste or smell * Sore throat * Congestion or runny nose * Nausea or vomiting * Diarrhea
次要结局
- Time until first occurrence of molecularly confirmed (RT-PCR-positive) symptomatic COVID-19 for CVXGA (CVXGA50) compared to COMIRNATY to determine durability(Day 1 to Day 366 post-vaccination.)
- Percentage of participants with asymptomatic COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY to determine relative efficacy.(Day 14 to Day 366 post-vaccination.)
- Percentage of participants with severe COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY to determine relative efficacy.(Day 14 to Day 366 post-vaccination.)
- The percentage of participants who experience any solicited local reactogenicity symptom pertaining to intranasal administration through 7 days post-vaccination.(Time Frame: Day 1 to Day 7 post-vaccination.)
- The percentage of participants who experience any solicited local reactogenicity symptom pertaining to intramuscular (IM) administration through 7 days post-vaccination.(Day 1 to Day 7 post-vaccination.)
- The percentage of participants who experience any solicited systemic reactogenicity symptom through 7 days post-vaccination.(Day 1 to Day 7 post-vaccination.)
- The percentage of participants who experience any unsolicited adverse event (AE) through 30 days post-vaccination.(Day 1 to Day 30 post-vaccination.)
- The percentage of participants who experience the following events through 12 months post-vaccination: o serious adverse events (SAEs) o medically attended adverse events (MAAEs) o adverse events of special interest (AESIs)(Day 1 to Day 366 post-vaccination.)
- The percentage of participants with any new or worsening clinically significant abnormal safety laboratory result (serum chemistries and hematology) through 7 days post-vaccination.(Day 1 to Day 7 post-vaccination.)
- Geometric mean titer (GMT) of SARS-CoV-2 specific neutralizing antibody (nAb) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.(Day 1 to Day 366 post-vaccination.)
- Geometric mean fold rise (GMFR) of SARS-CoV-2 specific nAb relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.(Day 1 to Day 366 post-vaccination.)
- GMT of anti-spike (S) protein-specific binding antibody (bAb) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.(Day 1 to Day 366 post-vaccination.)
- GMFR of S protein-specific bAb relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.(Day 1 to Day 366 post-vaccination.)
- GMT of S protein-specific IgA (nasal lining/saliva samples) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.(Day 1 to Day 366 post-vaccination.)
- GMFR of S protein-specific IgA (nasal lining/saliva samples) relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.(Day 1 to Day 366 post-vaccination.)
- The percentage of subjects with increases in S-specific cytokine increases by cell type.(Day 1 to Day 366 post-vaccination.)
研究者
研究点 (101)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy AdultsCOVID-19NCT05736835CyanVac LLC227
已完成
2 期
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)Painful Lumbosacral RadiculopathyNCT06176196Vertex Pharmaceuticals Incorporated218
已完成
2 期
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702Rheumatoid ArthritisNCT00205478Vertex Pharmaceuticals Incorporated300
已完成
2 期
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)Vulvar DysplasiaVulvar Intraepithelial Neoplasia (VIN)VIN2VIN3Pre-cancerous Lesions of the VulvaHuman Papillomavirus (HPV)NCT03180684Inovio Pharmaceuticals33
已完成
3 期
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular InflammationInflammationPainCataractNCT02235272Xigen SA339